Kyowa Hakko Kirin, Mochida Turn Focus To Orphan Drugs
This article was originally published in PharmAsia News
Executive Summary
A couple of smaller Japanese drug makers seek to profit from a focus on rare diseases largely ignored by the larger makers. Kyowa Hakko Kirin plans to begin trials this year on a drug to treat a certain type of leukemia with an eye on marketing it as early as 2013. Mochida Pharmaceutical sees a similar schedule for its drug to treat high blood pressure in lung arteries. Both firms are taking advantage of a Ministry of Health, Labor and Welfare program offering aid to companies that make orphan drugs. Israel's Teva Pharmaceutical Industries also seeks to take advantage of the program and begin trials on a multiple sclerosis treatment as soon as it can get the ministry's designation. (Click here for more - a subscription may be required
You may also be interested in...
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.